Book contents
- Frontmatter
- Contents
- Contributors
- Foreword
- Preface
- Introduction
- PART I PHYSIOLOGY OF REPRODUCTION
- PART II INFERTILITY EVALUATION AND TREATMENT
- 6 Evaluation of the Infertile Female
- 7 Fertiloscopy
- 8 Microlaparoscopy
- 9 Pediatric and Adolescent Gynecologic Laparoscopy
- 10 Laparoscopic Tubal Anastomosis
- 11 Tubal Microsurgery versus Assisted Reproduction
- 12 The Future of Operative Laparoscopy for Infertility
- 13 Operative Hysteroscopy for Uterine Septum
- 14 Laser in Subfertility
- 15 Ultrasonography of the Endometrium for Infertility
- 16 Ultrasonography of the Cervix
- 17 Transrectal Ultrasonography in Male Infertility
- 18 The Basic Semen Analysis: Interpretation and Clinical Application
- 19 Evaluation of Sperm Damage: Beyond the WHO Criteria
- 20 Male Factor Infertility: State of the ART
- 21 Diagnosis and Treatment of Male Ejaculatory Dysfunction
- 22 Ovulation Induction
- 23 Clomiphene Citrate for Ovulation Induction
- 24 Aromatase Inhibitors for Assisted Reproduction
- 25 Pharmacodynamics and Pharmacokinetics of Gonadotrophins
- 26 The Future of Gonadotrophins: Is There Room for Improvement?
- 27 Ovarian Hyperstimulation Syndrome
- 28 Reducing the Risk of High-Order Multiple Pregnancy Due to Ovulation Induction
- 29 Hyperprolactinemia
- 30 Medical Management of Polycystic Ovary Syndrome
- 31 Surgical Management of Polycystic Ovary Syndrome
- 32 Endometriosis-Associated Infertility
- 33 Medical Management of Endometriosis
- 34 Reproductive Surgery for Endometriosis-Associated Infertility
- 35 Congenital Uterine Malformations and Reproduction
- 36 Unexplained Infertility
- 37 “Premature Ovarian Failure”: Characteristics, Diagnosis, and Management
- PART III ASSISTED REPRODUCTION
- PART IV ETHICAL DILEMMAS IN FERTILITY AND ASSISTED REPRODUCTION
- Index
- Plate section
- References
23 - Clomiphene Citrate for Ovulation Induction
from PART II - INFERTILITY EVALUATION AND TREATMENT
Published online by Cambridge University Press: 04 August 2010
- Frontmatter
- Contents
- Contributors
- Foreword
- Preface
- Introduction
- PART I PHYSIOLOGY OF REPRODUCTION
- PART II INFERTILITY EVALUATION AND TREATMENT
- 6 Evaluation of the Infertile Female
- 7 Fertiloscopy
- 8 Microlaparoscopy
- 9 Pediatric and Adolescent Gynecologic Laparoscopy
- 10 Laparoscopic Tubal Anastomosis
- 11 Tubal Microsurgery versus Assisted Reproduction
- 12 The Future of Operative Laparoscopy for Infertility
- 13 Operative Hysteroscopy for Uterine Septum
- 14 Laser in Subfertility
- 15 Ultrasonography of the Endometrium for Infertility
- 16 Ultrasonography of the Cervix
- 17 Transrectal Ultrasonography in Male Infertility
- 18 The Basic Semen Analysis: Interpretation and Clinical Application
- 19 Evaluation of Sperm Damage: Beyond the WHO Criteria
- 20 Male Factor Infertility: State of the ART
- 21 Diagnosis and Treatment of Male Ejaculatory Dysfunction
- 22 Ovulation Induction
- 23 Clomiphene Citrate for Ovulation Induction
- 24 Aromatase Inhibitors for Assisted Reproduction
- 25 Pharmacodynamics and Pharmacokinetics of Gonadotrophins
- 26 The Future of Gonadotrophins: Is There Room for Improvement?
- 27 Ovarian Hyperstimulation Syndrome
- 28 Reducing the Risk of High-Order Multiple Pregnancy Due to Ovulation Induction
- 29 Hyperprolactinemia
- 30 Medical Management of Polycystic Ovary Syndrome
- 31 Surgical Management of Polycystic Ovary Syndrome
- 32 Endometriosis-Associated Infertility
- 33 Medical Management of Endometriosis
- 34 Reproductive Surgery for Endometriosis-Associated Infertility
- 35 Congenital Uterine Malformations and Reproduction
- 36 Unexplained Infertility
- 37 “Premature Ovarian Failure”: Characteristics, Diagnosis, and Management
- PART III ASSISTED REPRODUCTION
- PART IV ETHICAL DILEMMAS IN FERTILITY AND ASSISTED REPRODUCTION
- Index
- Plate section
- References
Summary
INTRODUCTION
Clomiphene revolutionized the management of infertility in 1967 when it was approved for treatment of anovulation due to polycystic ovaries (PCO). The clinical introduction of clomiphene followed six years of research (Greenblatt et al., 1961; Tyler et al., 1962; Vorys et al., 1964; Dickey et al., 1965; Kistner, 1966) cumulating in a report of results in 3,220 patients and 1,032 conceptions (Table 23.1) (Macgregor et al., 1967; Macgregor et al., 1968). Today, clomiphene remains the first-line treatment for WHO Group II anovulation in which ovarian activity can be demonstrated by withdrawal bleeding from progesterone. In addition to treatment of anovulation, clomiphene is now also used alone and in combination with human menopausal gonadotropin (HMG) and follicle-stimulating hormone (FSH) to increase the number of preovulatory follicles in patients with unexplained infertility (Melis et al., 1987; Deaton et al., 1990; Glazener et al., 1990), in patients requiring husband or donor intrauterine insemination (IUI) (Shalev et al., 1989; Dickey et al., 1992), and to increase progesterone in patients with luteal insufficiency (Hammond and Taubert, 1982; Fukuma et al., 1983; Dickey, 1984; Guzick and Zeleznik, 1990). The advantages of clomiphene over gonadotrophin for ovulation induction include low incidence of multiple pregnancies, low cost, ease of treatment, absence of need for daily cycle monitoring, and low incidence of ovarian hyperstimulation syndrome (OHSS) (Rizk, 2006, 2008; Rizk and Dickey 2008).
PHARMACOKINETICS AND PHARMACODYNAMICS
The pharmacokinetics and pharmacodynamics of clomiphene explain its characteristic actions. Clomiphene, chemical name 1-[p(β-diethylaminoethoxy)phenyl]-1,2-diphenylchloroethylene (Holtkamp et al., 1960), is related to other trianyl ethylene compounds chlorotrianisene, triparanol (a cholesterol inhibitor), and tamoxifen, a class of drugs called selective estrogen receptor modulators (Figure 23.1) and is distantly related to the nonsteroidal estrogen diethylstilbestrol.
Keywords
- Type
- Chapter
- Information
- Infertility and Assisted Reproduction , pp. 202 - 219Publisher: Cambridge University PressPrint publication year: 2008